All In Biotech

Drug Trial Radar · NCT07894887

EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)

Phase 1/2 Trial to Evaluate Safety, Tolerability, Pharmacokinetics, and Efficacy of EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

56

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jun 2029

Study completion Jul 2031

Sponsor

Lead sponsor
Editas Medicine, Inc.Industry
Sponsor type
Industry
First posted
Oct 26, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 1/2, two-part trial consisting of an open label dose-escalation part and a randomized, double blind, placebo-controlled part to investigate safety, tolerability, pharmacokinetics, and efficacy with EDIT-401 gene editing in adult male and female participants 18 to 65 years of age who require additional lowering of low-density lipoprotein cholesterol (LDL-C) such as those with clinical diagnosis of Heterozygous Familial Hypercholesterolemia (HeFH).

Conditions

  • Heterozygous Familial Hypercholesterolemia (HeFH)

Interventions

  • Drug: EDIT-401Drug

    Intravenous (IV) infusion

  • PlaceboOther

    Intravenous (IV) infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Time frame: Up to 2 years
  2. Part 2: Placebo-controlled percent change from baseline in serum LDL-CTime frame: Up to day 90

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Study Center

    Charlestown, New South Wales, Australia

  • Clinical Study Center

    Perth, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.